AHA 2022 – Idorsia and Cincor move forward in hypertension
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
The lowdown on high blood pressure
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.